Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Evolent Health, Inc. (EVH)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
37.06-0.35 (-0.94%)
At close: 04:00PM EDT
38.70 +1.64 (+4.43%)
After hours: 04:40PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • a
    a
    Healthcare are in a great position to accelerate in value, EVH is down >50% in a month which is an over reaction vs market w a beta of close to 1, further their sales are approaching $1B w a market cap at $450MM less than 50% of sales. The business has steadily improved EBITDA and is set to deliver a positive QTR soon. Under these circumstances it makes EVH an uniquely positioned buying opportunity. The fact the stock is dropping today is hard to decipher but for some over reactions/reallocations and potential margin calls. EVH meets the needs to reducing costs for the healthcare system representing the new way of healthcare and will benefit greatly from whats coming policy wise, and alike stocks addressing the healthcare systems with more efficiency such as TDOC which is valued at +10X sales.
  • p
    phil
    Baird Comments On Non-Renewal Of Passport's KY Medicaid Contract; Says Thinks Shares Will Be Range Bound ($6-$8) Until We Gain Insight On Potential Actions From Incoming KY Gov, Says Thinks It Is Possible He Will Redo Process And Award Passport A Contract
    10:21 am ET November 27, 2019 (Benzinga) Print
    Latest Ratings for EVH DateFirmActionFromTo

    Nov 2019MaintainsOverweight Mar 2019MaintainsOverweightOverweight Feb 2019MaintainsOverweightOverweight

    View More Analyst Ratings for EVH
    View the Latest Analyst Ratings

    © 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
  • J
    JohnD
    Canaccord Genuity Sticks to Its Buy Rating for Evolent

    Evolent Health (NYSE: EVH) Canaccord Genuity analyst Richard Close maintained a Buy rating on Evolent Health (EVH) yesterday and set a price target of $17.00. The company’s shares closed last Friday at $8.88.
  • C
    ComedyClubster
    EVH was trading in the $27-$28 range before Passport Health's travails cratered the pps. Now, with the sale to Molina it should slowly head back to the previous range, possibly higher because the rest of the business has grown. It will take a few months for that to happen. Slowly and steadily it will increase
    Bullish
  • J
    JohnD
    Timing is more uncertain than sequencing. Beshear will likely eliminate work requirements from Medicaid. That will justify a rebid on contracts. Passport will compete, and likely win, a share of new contract. Molina was the major beneficiary of Bevin’s original award - they have recently loss two other Medicaid state contracts.
    This will sort itself out within a few months - Long EVH
  • V
    Viking
    It doesn’t seem like a virus induced slowdown would decrease revenues for EVH. Hence I am still long but it might take a while to see movement besides a passport bump
  • M
    Michael
    I would like to hear how the will respond to this. Can they cut costs? How much net revenue will be lost? What is the liquidation value of passport if any? CEO mention he would liquidate passport according to an articLe.
  • M
    Matthew
    Missed on eps by just a little. Narrowed guidance. Best revenues. Partnership is really good.
  • J
    Julian
    Loading up every chance I got when it's under 10! Crazy opportunity here. Those who listened to the call yesterday would've heard that the total adjusted revenue for the quarter is up 46.7% from last year's, and anticipation of 20% growth in 2020.
    Bullish
  • S
    Sven O
    Spoken like their CFO - but let's get real for a moment. The EVH gross is always loosely correlated to the number of patients served by their clients. How have they increased that number of patients? Certainly not through the acquisition of new business. And organic growth has been what? Meanwhile, you talk about the elusive positive quarter while their enterprise value is in steady decline. The problem is, EVH is standing still while competitors aren't in a sector that is grow-or-die due to the advantages scale provides. Yes, there is some silver lining - but today's market, with EVH getting hit while the rest of the market rebounded feels like an accurate understanding of the company's flawed fundamentals. Show me multiple positive quarters. Or a significant new client. Or a new offering for existing clients. Or anything that says EVH is a growing concern.
    Bearish
  • M
    Michael
    More investors should look at this stock. Solid growth. Stable revenues during virus (if passport awarded, if not still facing growth I believe albeit smaller). Cash flow positive in the fall. Health care in dire need of reform. Good buy under $15.
    Bullish
  • B
    BullFight-2020
    Next week the journey to
    Double digits starts
  • J
    JohnD
    By Chris Larson – Reporter, Louisville Business First

    May 26, 2020, 7:10am EDT
    Two health care CEOs told investors and analysts that they expect to hear the Beshear administration's decision on which companies will administer the bulk of the state's Medicaid program soon.

    I purchased more at a $9.10 average during today's mini sell-off. Depending on option IV, I will likely purchase additional July calls if the decision isn't announced prior to June contract expiration and/or an additional stock price decline.
  • C
    ComedyClubster
    Just listened to the recording of today's call. I recommend it strongly. There is hope, actually a lot of it, because:
    1) they are appealing and many appeals are successful. Now there'll be a new Governor coming to KY on Dec 10 and his admin might well reverse this decision thus favoring Passport/EVH
    2) Even if the appeal fails, they can wind down and per the CEO recover substantially ALL of the investment minus the winding down costs
    3) Even if the appeal fails and they lose the business, they are well diversified and over the years should grow into a healthy, strong and profitable company
    4) They've been closing on a lot of other deals in other states. So this potential loss (if appeal is unsuccessful) will become progressively very small compared to their overall business.

    I wish I had the money to buy more! Lot's more
    Bullish
  • C
    ComedyClubster
    the management referred to Passport being on a much stronger footing now and that reimbursement rates had gone up in KY. so, the company is talking as if Passport and KY will do business together for years to come. If that is so, it might be with the feedback the company has received about Passports chances at securing a renewal of the contract. This seems to be positive which implies that we'll hear some good news on that front soon. I'm looking at this trading at $16 by end of June/mid July! Buy!
    Bullish
  • J
    JohnD
    Strong conference call.

    Evolent Health (EVH) PT Raised to $14 at SunTrust

    May 8, 2020 7:16 AM
    SunTrust analyst Sandy Draper raised the price target on Evolent Health (NYSE: EVH) to $14.00 (from $12.00) while maintaining a Buy rating.
  • C
    ComedyClubster
    Great results!!! On to $10 very soon!!!
    Bullish
  • J
    JohnD
    Stock continues to be accumulated - good news from KY in the 30-45 days?
  • C
    ComedyClubster
    remarkable strength. I think the pps was already priced for a second time denial. Around $8-$9 is perhaps closer to the true value of EVH. As the business strengthens it will rise..
Advertisement
Advertisement